MXPA03010945A - Mejoramiento de la biodisponibilidad oral de forumulaciones no esterificadas de esteres de profarmacos con lecitina. - Google Patents

Mejoramiento de la biodisponibilidad oral de forumulaciones no esterificadas de esteres de profarmacos con lecitina.

Info

Publication number
MXPA03010945A
MXPA03010945A MXPA03010945A MXPA03010945A MXPA03010945A MX PA03010945 A MXPA03010945 A MX PA03010945A MX PA03010945 A MXPA03010945 A MX PA03010945A MX PA03010945 A MXPA03010945 A MX PA03010945A MX PA03010945 A MXPA03010945 A MX PA03010945A
Authority
MX
Mexico
Prior art keywords
lecithin
emulsified
formulation
emulsified formulation
oral bioavailability
Prior art date
Application number
MXPA03010945A
Other languages
English (en)
Spanish (es)
Inventor
Gupta Pramod
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of MXPA03010945A publication Critical patent/MXPA03010945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03010945A 2001-05-29 2002-05-28 Mejoramiento de la biodisponibilidad oral de forumulaciones no esterificadas de esteres de profarmacos con lecitina. MXPA03010945A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86735301A 2001-05-29 2001-05-29
US29414101P 2001-05-29 2001-05-29
PCT/US2002/016428 WO2002096354A2 (en) 2001-05-29 2002-05-28 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin

Publications (1)

Publication Number Publication Date
MXPA03010945A true MXPA03010945A (es) 2004-02-27

Family

ID=26968357

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010945A MXPA03010945A (es) 2001-05-29 2002-05-28 Mejoramiento de la biodisponibilidad oral de forumulaciones no esterificadas de esteres de profarmacos con lecitina.

Country Status (5)

Country Link
EP (1) EP1401402B1 (enExample)
JP (1) JP5051865B2 (enExample)
CA (1) CA2449002C (enExample)
MX (1) MXPA03010945A (enExample)
WO (1) WO2002096354A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500712C (en) * 2002-10-02 2011-08-09 Meiji Seika Kaisha, Ltd. Antibiotic pharmaceutical composition with improved oral absorbability
EP1858488B2 (en) 2005-03-14 2022-07-20 Wyeth LLC Tigecycline compositions and methods of preparation
EP1954253A4 (en) * 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
JP2007106684A (ja) * 2005-10-11 2007-04-26 Sawai Pharmaceutical Co Ltd 抗菌性医薬組成物
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
WO2010066593A1 (en) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Combined drug administration
CN103781478A (zh) * 2011-06-24 2014-05-07 艾森达制药有限公司 用以改善酯类前药吸收率的方法与改良的药学组合物
KR101561963B1 (ko) * 2013-05-23 2015-10-22 영진약품공업 주식회사 세프디토렌 피복실의 신규 결정 형태 및 이의 제조 방법
EP3244879A1 (en) * 2015-01-16 2017-11-22 Ögün, Yusuf Toktamis Cefditoren pivoxil compositions with improved stability and production methods thereof
CN110143957B (zh) * 2019-06-20 2020-12-25 重庆医药高等专科学校 头孢妥仑匹酯开环物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58487B1 (en) 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPS6216431A (ja) * 1985-07-15 1987-01-24 Nakanishi Michio 医薬組成物
JPS62205088A (ja) 1986-03-03 1987-09-09 Meiji Seika Kaisha Ltd 新規セフエム化合物
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
WO1990015609A1 (en) * 1989-06-15 1990-12-27 Med-Tal, Inc. Prevention and treatment of microbial infection by phosphoglycerides
JP2785981B2 (ja) 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5319116A (en) 1992-02-12 1994-06-07 Gary Viole Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤
AR004014A1 (es) 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
AU4892897A (en) 1996-09-17 1998-04-14 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.

Also Published As

Publication number Publication date
EP1401402B1 (en) 2016-09-07
CA2449002C (en) 2011-08-16
EP1401402A4 (en) 2006-12-06
WO2002096354A2 (en) 2002-12-05
JP2005515155A (ja) 2005-05-26
CA2449002A1 (en) 2002-12-05
WO2002096354A3 (en) 2003-03-20
JP5051865B2 (ja) 2012-10-17
EP1401402A2 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
WO1997015269A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2003064431A3 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AU629977B2 (en) 4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, process for their preparation, their use as pharmaceuticals, and pharmaceutical preparations and precursors
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
GEP20043287B (en) Pharmaceutical Composition Containing Fenofibrate and Method for Its Production
CA2133175A1 (en) Rapamycin formulations for oral administration
HUT54144A (en) Process for producing 3-desmethylmevalonic acid derivatives and pharmaceutical compositions comprising same as active ingredient
MX373796B (es) Composición de solubilización farmacéuticamente aceptable y forma de dosificación farmacéutica que contiene la misma.
AU2581888A (en) Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations
WO2002096354A3 (en) Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
AU2975195A (en) Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
MA28215A1 (fr) Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
AU5861499A (en) Agitation-independent pharmaceutical multiple unit retard preparations and method for the production thereof
DE69919533D1 (de) Proteinhaltige arzneimittel
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
HUP9801052A2 (hu) Orális ciklosporin készítmények
EP1057828A3 (en) Trovafloxacin oral suspensions
CA2483916A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
HUT49614A (en) Process for producing cefalosporin derivatives and pharmaceutical compositions comprising these compounds
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
WO2003039437A3 (de) Oral verabreichbare pharmazeutische zubereitung umfassend liposo mal verkapseltes taxol

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status